Literature DB >> 31489303

A prognostic nomogram for patients with resected fibrolamellar hepatocellular carcinoma.

Kelly J Lafaro1, Oliver S Eng1, Mustafa Raoof1, Philip Ituarte1, Susanne G Warner1, Gagandeep Singh1, Yuman Fong1, Laleh G Melstrom1.   

Abstract

BACKGROUND: Fibrolamellar hepatocellular carcinoma (FLHC) is a unique entity compared to conventional hepatocellular carcinoma. The aim of this study was to examine post-resection outcomes and prognostic indicators for survival in this group of FLHC patients.
METHODS: A retrospective analysis of the National Cancer Database (NCDB) for patients with FLHC who underwent resection from 2004 to 2014 was performed. Univariate and multivariate Cox proportional hazard models were used to identify factors associated with overall survival, and a prognostic nomogram was generated.
RESULTS: There were 197 patients identified, 171 (86.8%) of whom had long-term follow-up data. Univariate and multivariate analyses were performed using patient and tumor demographics with the outcome variable of overall survival. On multivariate analysis, age [hazard ratio (HR) 1.03, P=0.003], vascular invasion (HR 1.75, P=0.05), tumor size >7 cm (HR 2.18, P=0.044), multifocal disease (HR 3.34, P=0.002), and node positive (pN+) disease (HR 2.75, P=0.003) were all negative predictors of overall survival. A prognostic nomogram was generated using these factors with a c-statistic superior to that of American Joint Committee on Cancer (AJCC) staging (0.710 vs. 0.654).
CONCLUSIONS: Independent predictors of decreased overall survival in patients with FLHC include age, vascular invasion, tumor size >7 cm, multifocal disease, and pN+ disease. This is the first study to develop a nomogram exclusively for FLHC that may predict survival in future studies.

Entities:  

Keywords:  Fibrolamellar hepatocellular carcinoma (FLHC); liver resection; overall survival

Year:  2019        PMID: 31489303      PMCID: PMC6700009          DOI: 10.21037/hbsn.2019.05.03

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN: 2304-3881            Impact factor:   7.293


  20 in total

1.  Multi-institutional analysis of recurrence and survival after hepatectomy for fibrolamellar carcinoma.

Authors:  Ryan T Groeschl; John T Miura; Ray K Wong; Mark Bloomston; Michael L Lidsky; Bryan M Clary; Robert C G Martin; Giulio Belli; Joseph F Buell; T Clark Gamblin
Journal:  J Surg Oncol       Date:  2014-05-21       Impact factor: 3.454

2.  Hepatocellular carcinoma in children: epidemiology and the impact of regional lymphadenectomy on surgical outcomes.

Authors:  Jarod P McAteer; Adam B Goldin; Patrick J Healey; Kenneth W Gow
Journal:  J Pediatr Surg       Date:  2013-11       Impact factor: 2.545

3.  Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma.

Authors:  Joshua N Honeyman; Elana P Simon; Nicolas Robine; Rachel Chiaroni-Clarke; David G Darcy; Irene Isabel P Lim; Caroline E Gleason; Jennifer M Murphy; Brad R Rosenberg; Lydia Teegan; Constantin N Takacs; Sergio Botero; Rachel Belote; Soren Germer; Anne-Katrin Emde; Vladimir Vacic; Umesh Bhanot; Michael P LaQuaglia; Sanford M Simon
Journal:  Science       Date:  2014-02-28       Impact factor: 47.728

4.  Comparison of commission on cancer-approved and -nonapproved hospitals in the United States: implications for studies that use the National Cancer Data Base.

Authors:  Karl Y Bilimoria; David J Bentrem; Andrew K Stewart; David P Winchester; Clifford Y Ko
Journal:  J Clin Oncol       Date:  2009-07-27       Impact factor: 44.544

Review 5.  A systematic review: treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma.

Authors:  Michael N Mavros; Skye C Mayo; Omar Hyder; Timothy M Pawlik
Journal:  J Am Coll Surg       Date:  2012-09-13       Impact factor: 6.113

6.  Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study.

Authors:  Hashem B El-Serag; Jessica A Davila
Journal:  Hepatology       Date:  2004-03       Impact factor: 17.425

7.  Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium.

Authors:  Celina S Ang; R Katie Kelley; Michael A Choti; David P Cosgrove; Joanne F Chou; David Klimstra; Michael S Torbenson; Linda Ferrell; Timothy M Pawlik; Yuman Fong; Eileen M O'Reilly; Jennifer Ma; Joseph McGuire; Gandhi P Vallarapu; Ann Griffin; Francesco Stipa; Marinela Capanu; Ronald P Dematteo; Alan P Venook; Ghassan K Abou-Alfa
Journal:  Gastrointest Cancer Res       Date:  2013-01

8.  Outcome of patients with fibrolamellar hepatocellular carcinoma.

Authors:  Francesco Stipa; Sam S Yoon; Kui Hin Liau; Yuman Fong; William R Jarnagin; Michael D'Angelica; G Abou-Alfa; Leslie H Blumgart; Ronald P DeMatteo
Journal:  Cancer       Date:  2006-03-15       Impact factor: 6.860

Review 9.  Fibrolamellar variant of hepatocellular carcinoma.

Authors:  Yun Shin Chun; Giuseppe Zimmitti
Journal:  Recent Results Cancer Res       Date:  2013

10.  Clinical and pathologic factors associated with survival in young adult patients with fibrolamellar hepatocarcinoma.

Authors:  Laura E Moreno-Luna; Oscar Arrieta; Jorge García-Leiva; Braulio Martínez; Aldo Torre; Misael Uribe; Eucario León-Rodríguez
Journal:  BMC Cancer       Date:  2005-10-31       Impact factor: 4.430

View more
  2 in total

1.  Development and validation of a nomogram for predicting the cancer-specific survival of fibrolamellar hepatocellular carcinoma patients.

Authors:  Jiawei Hu; Yi Wang; Liming Deng; Haitao Yu; Kaiyu Chen; Wenming Bao; Kaiwen Chen; Gang Chen
Journal:  Updates Surg       Date:  2022-06-17

2.  Factors Influencing Overall Survival for Patients with Fibrolamellar Hepatocellular Carcinoma: Analysis of the Surveillance, Epidemiology, and End Results Database.

Authors:  Georgios Polychronidis; Jincheng Feng; Anastasia Murtha-Lemekhova; Ulrike Heger; Arianeb Mehrabi; Katrin Hoffmann
Journal:  Int J Gen Med       Date:  2022-01-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.